Completed PHASE1 INTERVENTIONAL 4-arm NCT00922740

VA106483 Dose Response Study in Elderly Males

An Open Label, Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Elderly Male Subjects

Sponsor: Vantia Ltd

Conditions Nocturia

Updated 6 times since 2017 Last updated: May 21, 2018 Started: Jun 30, 2009 Primary completion: Jul 31, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Nocturia and is currently completed. Vantia Ltd leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vantia Ltd

Data source: Vantia Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States